Compare Ascendis Pharma A/S (ASND) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Extra Space Storage, Inc. — how do they compare? Ascendis Pharma A/S trades at $255.17 (market cap $16.67B), while Extra Space Storage, Inc. trades at $147.15 (market cap $30.96B). The key difference: Extra Space Storage, Inc. is the larger of the two by market cap, and Extra Space Storage, Inc. pays a 4.42% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | EXR | |
|---|---|---|
Market Cap | $16.67B | $30.96B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $152.85 |
52-Week Low | $189.74 | $126.67 |
Enterprise Value | $17.04B | $44.68B |
Dividend Yield | — | 4.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
EXR trades at $147.22, up 0.38% today, near its 52-week high with a consensus price target of $157.25. The stock shows strong fundamentals, with Q2 2026 EPS beating estimates and a dividend yield supported by robust cash flow. Technicals are bearish on moving averages but neutral on oscillators, with key resistance at $148. Revenue growth has been steady, and the company maintains high profitability margins.
Outlook is positive with consistent earnings beats and a solid balance sheet, though high valuation multiples and competitive pressures pose risks. Analysts are mixed with a 'Hold' consensus, but institutional interest remains strong. The stock offers growth potential but requires monitoring of debt levels and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
